Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major antibody categories: those to the acetylcholine receptor (AChR ...

The FDA has approved Alexion's Soliris for use in patients with treatment resistant generalised Myasthenia gravis (gMG), making it the first new therapy for the condition in 60 years. The approval ...

Heightened focus on delays in diagnosing generalized myasthenia gravis (gMG) follows the promise of better results for some patients with newer treatments that include complement inhibitors and ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

An increase in the concentration of ionized Ca in the extracellular fluids is the major feedback mechanism that inhibits PTH secretion from the parathyroid glands and possibly also from the thymus ...